381 articles in this topic
A comprehensive review in CA Cancer J Clin maps the molecular biology, treatment strategies, and equity gaps in high-grade serous ovarian cancer.
New research reveals how lung cancer subclones develop distinct immune evasion strategies, complicating immunotherapy response.
New research reveals how corticotroph pituitary tumors develop resistance to temozolomide through clonal selection of high MGMT-expressing cells.
A multinational study of 4,913 patients finds EBRT delivers survival outcomes comparable to surgery and ablation for early hepatocellular carcinoma.
Adding targeted radiation to standard therapy reduced progression by 46% across multiple cancer types in the EXTEND trial.
A randomized trial shows hormone receptor-positive/HER2+ early breast cancer patients had 100% 5-year overall survival with endocrine therapy plus dual HER2 blockade.
Orally bioavailable cyclin A/B RxL inhibitors exploit a cell-cycle vulnerability in small-cell lung cancer and other G1-S-checkpoint-deficient tumors.
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
Scientists identify CD300ld as a key mechanism by which tumor-infiltrating neutrophils silence CD8+ T cells, opening a new immunotherapy target.
A prospective cohort study shows combining ctDNA with PSA levels dramatically improves survival prediction in high-volume metastatic prostate cancer patients.
Stanford scientists used RFdiffusion and ProteinMPNN to build a compact ฮฑ-helical TCR mimic with 9.5 nM affinity for a tumor antigen โ and near-perfect peptide specificity.
A new machine learning tool called MaNeo scans tumor peptides to identify neoantigens that activate T cells against cancer while sparing healthy cells.
